Cochrane Db Syst Rev
-
Cochrane Db Syst Rev · Aug 2018
Meta AnalysisNatalizumab for induction of remission in Crohn's disease.
This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn's disease (CD). ⋯ High quality data suggest that natalizumab is effective for induction of clinical remission and response in some patients with moderately to severely active CD. However, none of the included studies had the power to detect rare but serious adverse events such as PML. Due to the association with PML, and the availability of alternative agents that are not associated with PML, natalizumab is not likely to be used in patients who fail currently available medical therapy. The use of natalizumab in select patients (e.g. patients allergic to different biologics) needs to be carefully considered against the potential risk of developing PML. Futher studies of natalizumab are not likely to be done.